West Pharmaceutical Services, Inc. (NYSE:WST) Q3 2024 Results Earnings Conference Call October 24, 2024 9:00 AM ET
Company Participants
John Sweeney – Vice President, Investor Relations
Eric Green – Chairman, President and Chief Executive Officer
Bernard Birkett – Senior Vice President, Chief Financial Officer
Conference Call Participants
Jacob Johnson – Stephens Inc.
Lawrence Solow – CJS Securities
Michael Ryskin – BofA Global Research
David Windley – Jefferies
Matthew Larew – William Blair & Company
Justin Bowers – Deutsche Bank
Thomas DeBourcy – Nephron Research
Operator
Good day and thank you for standing by. Welcome to the Q3 2024 West Pharmaceutical Services Earnings Conference Call. At this time, all participants are in a listen-only mode. After the speakers’ presentation, there will be a question-and-answer session. [Operator Instructions]. Please be advised that today’s conference is being recorded.
I would now like to hand the conference over to your speaker today, John Sweeney, VP of Investor Relations with West Pharmaceuticals. Please go ahead.
John Sweeney
Good morning. And welcome to West’s second quarter 2024 conference call. We issued our financial results earlier this morning, and the release has been posted to the Investors section on the company’s website located at westpharma.com.
On the call today, we will review our financial results, provide an update on our business, and present an updated financial outlook for the full-year 2024. There is a slide presentation that accompanies today’s call and a copy of the presentation is available on the Investors’ section of our website.
On slide 4 is our Safe Harbor statements. Statements made by management on this call and the accompanying presentation contain forward-looking statements within the meaning of the US Federal Securities Laws. These statements are based on our beliefs and assumptions, current expectations, estimates and forecasts. The company’s future results are influenced by many factors beyond the control
